Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ozanimod Hydrochloride

FDA-approved product (capsule, oral), marketed as Zeposia.

Registered studies
7
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ozanimod Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Multiple sclerosis
  • Relapsing-remitting multiple sclerosis
  • Ulcerative colitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sphingosine-1-phosphate (s1p) receptor modulators
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

7registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ozanimod Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ozanimod Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

    NCT06408259 · start 2025-04-08

    Registered record
    Registry ID
    NCT06408259
    Conditions
    Multiple Sclerosis, Relapsing-Remitting
    Interventions
    Ozanimod; Fingolimod; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-04-08
    Completion
    2036-07-13
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis, Relapsing-Remitting
    InterventionOzanimod; Fingolimod; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

    NCT05688436 · start 2021-09-24

    Registered record
    Registry ID
    NCT05688436
    Conditions
    Multiple Sclerosis
    Interventions
    Diroximel Fumarate; Alemtuzumab; Fingolimod; Glatiramer acetate; Interferon beta; Natalizumab; Ocrelizumab; Ofatumumab; Ozanimod; Peginterferon beta-1a; Ponesimod; Siponimod
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2021-09-24
    Completion
    2031-01-17
    Enrolment
    1,178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionDiroximel Fumarate; Alemtuzumab; Fingolimod; Glatiramer acetate +8 more
    PhaseNot recorded
    Registry statusActive not recruiting

  • Relationship Between Oral DMT Burden and Adherence in MS

    NCT04676204 · start 2020-09-25

    Registered record
    Registry ID
    NCT04676204
    Conditions
    Multiple Sclerosis; Adherence, Medication
    Interventions
    Cladribine; Dimethyl fumarate; Fingolimod; Teriflunomide; Ozanimod; Diroximel fumarate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-09-25
    Completion
    2026-07-11
    Enrolment
    323

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis; Adherence, Medication
    InterventionCladribine; Dimethyl fumarate; Fingolimod; Teriflunomide +2 more
    PhaseNot recorded
    Registry statusUnknown

  • Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

    NCT03535298 · start 2019-01-03

    Registered record
    Registry ID
    NCT03535298
    Conditions
    Multiple Sclerosis, Relapsing-Remitting
    Interventions
    Early Highly Effective Therapies Group; Escalation Therapies Group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2019-01-03
    Completion
    2027-07-30
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis, Relapsing-Remitting
    InterventionEarly Highly Effective Therapies Group; Escalation Therapies Group
    PhasePhase 4
    Registry statusActive not recruiting

  • Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

    NCT03500328 · start 2018-05-02

    Registered record
    Registry ID
    NCT03500328
    Conditions
    Multiple Sclerosis, Relapsing-Remitting
    Interventions
    Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq; Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2018-05-02
    Completion
    2026-09
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis, Relapsing-Remitting
    InterventionNatalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq; Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
    PhaseNot applicable
    Registry statusActive not recruiting

  • A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults

    NCT02994381 · start 2016-10

    Registered record
    Registry ID
    NCT02994381
    Conditions
    Healthy Volunteers
    Interventions
    RPC1063
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-10
    Completion
    2016-11
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionRPC1063
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

    NCT01647516 · start 2012-12-26

    Registered record
    Registry ID
    NCT01647516
    Conditions
    Ulcerative Colitis
    Interventions
    Ozanimod; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12-26
    Completion
    2019-08-30
    Enrolment
    199

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis
    InterventionOzanimod; Placebo
    PhasePhase 2
    Registry statusCompleted